Due to the modest benefit, inconvenience and high cost of currently available therapies for MS, it is appropriate to seek alternative treatments. Based on anecdotal evidence suggestive of benefit for IVIG in MS, we conducted an open-label, unblinded protocol of IVIG in nine MS patients. The patients were given induction doses of IVIG followed by monthly boosters for I year and had clinical, MRI and CSF analyses performed. Patients included were both progressive and relapsing. There was no clinical benefit nor apparent MRI benefit utilizing this protocol. During treatment, the majority of patients continued to progress or have attacks and MRI demonstrated continued accumulation of T2-weighted lesions. CSF was unaffected by treatment
Francis GS, Duquette P., Antel JPInflammatory demyelinating diseases of the CNS. In: Bradley WG, Daroff RB , Fenichel GM, Marsden CD, (eds). Neurology in clinical practice. 2nd ed. Newton, MA: Butterworth Publishers , 1995: 1307 -1343.
2.
IFNB Multiple sclerosis study group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 655-661.
3.
IFNB Multiple sclerosis study group, University of BC MS/MRI Analysis Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology45: 1277-1285.
4.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM (1996) Intramuscular interferon Beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol39: 285 - 294.
5.
Johnson KP, Brooks BR, Cohen JA, Ford CC et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology45: 1268 -1276.
6.
Bourdette DN , Prochazka AV, Mitchell W., Licari P. et al. (1993) Health care costs of veterans with multiple sclerosis: Implications for the rehabilitation of MS. Arch Phys Med Rehabil74: 26-31.
7.
Buckley RH, Schiff RI (1991) The use of intravenous immune globulin in immunodeficiency diseases. NEngl J Med325: 110 -117.
8.
Newburger JW , Takahashi M., Beiser AS, Burns JC et al. (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med324: 1633 -1639.
9.
van der Meche Fga , Schmitz Pim, Dutch Guillain-Barre Study Group. (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain Barre syndrome . N Engl J Med326: 1123-1129.
10.
van Doorn PA , Rossi F., van Lint M., Vermeulen M. (1990) On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol29: 57-64.
11.
van Doorn PA , Brand MD, Strengers Pfw, Meulstee J. et al. (1990 ) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy . Neurology40: 209-212.
12.
Cherin P., Herson S. et al. (1991) Efficacy of intravenous gamma globulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med91: 162 -168.
13.
Dalakas MC, Illa I., Dambrosia JM, Soueidan SA et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med329: 1993 - 2000.
14.
Achiron A., Gilad R., Margalit R., Gabbay U. et al. (1994) Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis : delineation of usage and mode of action. J Neurol Neurosurg Psychiatry57: 57-61.
15.
Achiron A., Cohen IR, Lider 0, Melamed E.(1995) Intravenous immunoglobulin treatment in multiple sclerosis . Israel J Med Sci31: 7 - 9.
16.
Tan E., Hajinazarian M., Bay W., Neff J. et al. (1993) Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol50: 137-139.
17.
Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology44: 223 - 226.
18.
Schiff RI (1994) Transmission of viral infections through intravenous immune globulin. N Engl J Med331: 1649- 1650.
19.
Dawson WB, Phillips LH (1995) A comparison between IVIg and plasma exchange in Guillain-Barre syndrome: A review and decision analysis of the two treatment modalities. Clinical Neuropharmacology18: 377-390.
20.
van der Meche Fga , Schnitz Pim, Dutch Guillain-Barre Study Group. (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome . N Engl J Med326: 1123 -1129.
21.
Hahn AF, Bolton CF, Zochodne D., Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. Brain119: 1067-1077.
22.
van den Berg LH, Kerkhoff H., Oey PL, et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psy59: 248-252.
23.
Edan G., Landgraf F. (1994) Experience with intravenous immunoglobulin in myasthenia gravis: a review. JNeurol Neurosurg Psychiatry57: 55 - 56.
24.
Bain PG, Motomurs M, Newsom-Davis J et al. (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology47: 678 - 683.
25.
Phuphanich S., Brock C., Roberts W., Prockop L. (1996) Neurologic improvement after high-dose intravenous immunoglobulin therapy in paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. Neurology46(2): A129
26.
Francis GS, Arnaoutelis R., Antel J. (1994) Lack of efficacy of IVIG in multiple sclerosis . Neurology44(2): A357-A358. Abstract.
27.
Schuller E. , Govaerts A. (1983) First results of immunotherapy with immunoglobulin- gamma in multiple sclerosis patients . Eur Neurol22: 205-212.
28.
Leger JM, Mariette X., Chastang C., Clavelou P. et al. (1996) A randomized trial comparing alpha-interferon and intravenous immunoglobulin in polyneuropathy associated with IgM monoclonal gammopathy. Neurology46(2): A380.
29.
Wokke Jhj , van den Berg LH, Franssen H., Oey PL (1996) The long-term effect of intravenous immunoglobulin treatment in patients with multifocal motor neuropathy . Neurology46(2): A381.
30.
Cappa M., Bertini E., del Balzo P., Cambiaso P. et al. (1994) Discussion on: High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry57: 71.
31.
van Engelen Bgm , Renier WO, Weemaes Cmr. (1994) Immunoglobulin treatment in human and experimental epilepsy. J Neurol Neurosurg Psychiatry57: 72 - 75.
32.
Harris JO, Frank JA, Patronas N., McFarlin DE et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol29: 548-555.
33.
McFarland HF , Frank JA, Albert PS, Smith ME et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol32: 758 - 766.
34.
Paty DW, Li Dkb, UBC Study Group, IFNB Multiple sclerosis study group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis; II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662-667.
35.
Koopmans RA , Li Dkb, Zhao GJ, Redekop K. et al. (1992) MRI assessment of cyclosporine therapy of MS in a multicenter trial. Neurology42: 244 Abstract.
36.
Palmer MR, Bergstrom M., Grochowski E., Apted C. et al. (1986) Magnetic resonance imaging (MRI) in multiple sclerosis (MS): quantitation changes in the size of lesions over 6 months in the placebo limb of a therapeutic trial. Can J Neurol Sci13: 168.
37.
Miller DH, Albert PS, Barkhof F., Francis G. et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol39: 6 -16.
38.
Schumacher GA, Beebe GW, Kibler RF, Kurland LT et al. (1965) Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci122: 552 -568.
39.
Poser CM, Paty DW, Scheinberg L., McDonald WI et al. (1983) New diagnostic criteria for Multiple Sclerosis: guidelines for research protocols. Ann Neurol13: 227-231.
40.
van Engelen Bgm , Hommes OR, Pinckers A., Cruysberg Jrm et al. ( 1992) Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol32: 834-835.
41.
Dwyer JM (1992) Manipulating the immune system with immune globulin . N Engl J Med326: 107 -116.
42.
Achiron A., Margalit R., Hershkoviz R., Markovits D. et al. (1994) Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease: Up-regulation of T cell proliferation and down-regulation of tumor necrosis factor-α secretion. J Clin Invest93: 600 - 605.
43.
Rodriguez M. , Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol27: 12 -17.
44.
Rodriguez M. , Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination . Neurology46: 538-545.
45.
van Engelen Bgm , Miller D., Pavelko KD, Hommes OR et al. (1994) Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry57: 65 - 68.
46.
Noseworthy JH, O'Brien PC, van Engelen Bgm, Rodriguez M. (1994) Intravenous immunoglobulin therapy in multiple sclerosis: Progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial . J Neurol Neurosurg Psychiatry57: 11-14.
47.
Noseworthy JH, Weinshenker BG, O'Brien P. et al. (1997) Intravenous immunoglobulin does not reverse recently acquired, apparently permanent weakness in Multiple Sclerosis. Ann Neurol42: 421 Abstract.
48.
Miller HG, Foster JB, Newell DJ, Barwick DD et al. (1963) Multiple sclerosis: Therapeutic trials of chloroquine, soluble aspirin, and gammaglobulin. Br Med J2:1436-1439.
49.
Cook SD, Troiano R., Rohowsky-Kochin C., Jotkowitz A., et al. (1992) Intravenous gamma globulin in progressive MS. Acta Neurol Scand86: 171∼175.
50.
Achiron A., Pras E., Gilad R., Ziv I. et al. (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol49: 1233-1236.
51.
Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G. et al. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis . Lancet349: 589-593.
52.
Soelberg-Sørensen P., Wanscher B., Schreiber K., Blinkenberg M. et al. (1997 ) A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Prelininary results. Multiple Sclerosis3: 145 - 148.
53.
Weinshenker BG , Bass B., Rice Gpa, Noseworthy JH, et al. (1989 ) The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain112: 133 -146.
54.
Pozzilli C., Bastianello S., Koudriavsteva T., Gasperini C. et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry61: 251- 258.
55.
Balashov EK , Smith DR, Khoury SJ, Hafler DA et al. (1997) Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA94: 599-603.
